The FDA has greenlit niraparib and abiraterone acetate (AAP; Akeega) with prednisone for the treatment of adults with deleterious or suspected deleterious BRCA2 -mutated metastatic hormone-sensitive ...

Onc Nurse On Call is the new podcast by Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, AOCN, and ...

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of ...

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

Lillian Rodich, PA-C, MPH, is an integrative oncology physician assistant at Memorial Sloan Kettering Cancer Center Bendheim Integrative Medicine Center in New York, New York. Lillian Rodich, PA-C, ...

Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

The combination of carfilzomib (Kyprolis) plus lenalidomide (Revlimid) and dexamethasone (KRd) improved progression-free ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

Blinatumomab/ponatinib increased efficacy and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.